Effector and predisposing genes in murine lupus

Lupus

Volumn 7, Issue 9, 1998, Pages 575-584

  Theofilopoulos, A N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; Gene; Genomic map; Knock out mice; Transgenic mice

Indexed keywords

AUTOIMMUNITY; GENETIC PREDISPOSITION; KNOCKOUT GENE; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; GENES; GENETIC PREDISPOSITION TO DISEASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 0032445083     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920686     Document Type: Review

References (119)

1. Buhl AM, Cambier JC. Co-receptor and accessory regulation of B-cell antigen receptor signal transduction. Immunol Rev 1997; 160: 127-138.
2. Healy JI, Goodnow CC. Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol 1998; 16: 645-670.
3. Hibbs ML et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83: 301-311.
4. Chan VW et al. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997; 7: 69-81.
5. Nishizumi H et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995; 3: 549-560.
6. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996; 274: 798-801.
7. Shultz LD et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993; 73: 1445-1454.
8. Tsui HW, Siminovitch KA, deSouza L, Tsui FWL. Motheaten and viable motheaten mice have mutations in the hematopoeitic cell phosphatase gene. Nat Genet 1993; 4: 124-129.
9. Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T. A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals. J Exp Med 1998; 187: 1343-1348.
10. Cornall RJ et al. Polygenic autoimmune traits: Lyn, CD22 and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998; 8: 497-508.
11. Chan VW, Lowell CA, DeFranco AL. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes. Curr Biol 1998; 8: 545-553.
12. Kato J et al. Affinity maturation in Lyn kinase-deficient mice with defective germinal center formation. J Immunol 1998; 160: 4788-4795.
13. Nitschke L et al. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997; 7: 133-143.
14. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481-504.
15. Yu CC et al. B and T cells are not required for the viable motheaten phenotype. J Exp Med 1996; 183: 371-380.
16. Smith KGC et al. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med 1998; 187: 807-811.
17. Wang J. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996; 184: 831-838.
18. Cambier JC. Inhibitory receptors abound? Proc Natl Acad Sci USA 1997; 94: 5993-5995.
19. Tridandapani S et al. Negative signaling in B cells: SHIP Grbs Shc. Immunol Today 1997; 18: 424-427.
20. Coggeshall KM. Inhibitory signaling by B cell Fc gamma RIIb. Curr Opin Immunol 1998; 10: 306-312.
21. D'Ambrosio D et al. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc-gamma RIIB1. Science 1995; 268: 293-297.
22. Nadler MJS et al. Protein-tyrosine phosphatase SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of B cell antigen receptor activation. J Biol Chem 1997; 272: 20038-20043.
23. Tivol EA et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
24. Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol 1996; 8: 822-830.
25. Waterhouse P et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-988.
26. Tivol EA et al. CTLA-4 Ig prevents lymphoproliferative and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997; 158: 5091-5094.
27. Taylor GA et al. A pathogenetic role for TNFα in the syndrome of cachexia, arthritis and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996; 4: 445-454.
28. Carballo E, Gilkeson GS, Blackshear PJ. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/ macrophage progenitors may be responsible for TNFalpha overproduction. J Clin Invest 1997; 100: 986-995.
29. Dang H et al. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995; 155: 3205-3212.
30. + T cells. Eur J Immunol 1995; 25: 3053-3059.
31. Willerford DM et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3: 521-530.
32. Suzuki H et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 1995; 268: 1472-1476.
33. van Parijs L et al. Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J Immunol 1997; 158: 3738-3745.
34. Refaeli Y et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8: 615-623.
35. Adachi M et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996; 93: 2131-2136.
36. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann NY Acad Sci 1997; 815: 267-281.
37. Botto M et al. Homozygous C1q deficiency caused glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-59.
38. Carroll MC. The lupus paradox. Nat Genet 1998; 19: 3-4.
39. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998; 16: 545-568.
40. Cutler AJ et al. T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells. J Exp Med 1998; 187: 1789-1797.
41. Hammerberg C, Katiyar SK, Carroll MC, Cooper KD. Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J Exp Med 1998; 187: 1133-1138.
42. Strasser A et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661-8665.
43. McDonnell TJ et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
44. Katsumata M et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1998; 89: 11376-11380.
45. Lopez-Hoyos M et al. Constitutive expression of bcl-2 in B cells causes a lethal form of lupus-like autoimmune disease after induction of neonatal tolerance to H-2b alloantigens. J Exp Med 1996; 183: 2523-2531.
46. Nisitani S et al. The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow. J Exp Med 1993; 178: 1247-1254.
47. Hartley SB et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993; 72: 325-335.
48. Lang J et al. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen-dependent manner and promotes receptor editing in autoreactive, immature B cells. J Exp Med 1997; 186: 1513-1522.
49. Hande S, Notidis E, Manser T. Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development. Immunity 1998; 8: 189-198.
50. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-283.
51. Seery JP, Carroll JM, Cattell V, Watt FM. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997; 186: 1451-1459.
52. Erb KJ et al. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 852: 329-339.
53. Muller W, Kuhn R, Rajewsky K. Major histocompatibility complex class II hyperexpression on B cells in interleukin 4-transgenic mice does not lead to B cell proliferation and hypergammaglobulinemia. Eur J Immunol 1991; 21: 921-925.
54. Lewis DB et al. Interleukin 4 expressed in situ selective alters thymocyte development. J Exp Med 1991; 173: 89-100.
55. Theofilopoulos AN, Kono DH. Murine lupus models: gene-specific and genome-wide studies. In: Lahita RG (ed.) Systeme Lupus Erythematosus 3rd edition. Academic Press: San Diego, 1998 (in press).
56. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107-118.
57. Sato S et al. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157: 4371-4378.
58. Inaoki M et al. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997; 186: 1923-1931.
59. Zhang L et al. An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes. Mol Cell Biol 1995; 15: 6961-6970.
60. Bullard DC et al. Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas (lpr) mice from early lethality. J Immunol 1997; 159: 2058-2067.
61. Lloyd CM. Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas (lpr) mice from early lethality. J Clin Invest 1997; 100: 963-967.
62. Gilkeson GS et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med 1997; 186: 365-373.
63. G-monomethyl-L-arginine. J Exp Med 1994; 179: 651-660.
64. Oates JC et al. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 1997; 83: 86-92.
65. Jevnikar AN, Grusby MJ, Glimcher LH. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J Exp Med 1994; 179: 1137-1143.
66. Koh DR et al. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995; 25: 2558-2562.
67. Maldonado MA et al. Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I. J Exp Med 1995; 181: 641-649.
68. + double-negative T cells as the predominant population in enlarged lymph nodes. J Immunol 1995; 154: 4986-4995.
69. + T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecules. Eur J Immunol 1995; 25: 37-41.
70. 2-Microglobulin dependence of the lupus-like autoimmune syndrome of MKL-lpr mice. J Immunol 1996; 156: 4932-4939.
71. Herron LR et al. Selection of the T cell receptor repertoire in lpr mice. J Immunol 1993; 151: 3450-3459.
72. Giese T, Davidson WF. Chronic treatment of C3H-lpr/lpr and C3H-gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double-negative T cells but not autoantibody production. J Immunol 1994; 152: 2000-2010.
73. Peng SL et al. Alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 1997 158: 2464-2470.
74. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA-4Ig. Science 1994; 265: 1225-1227.
75. + cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA-4Ig. J Immunol 1996; 156: 1262-1268.
76. Nakajima A et al. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol 1995; 25: 3060-3069.
77. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
78. Daikh DI et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 3104-3108.
79. Peng SL et al. Murine lupus in the absence of αβ T cells. J Immunol 1996; 156: 4041-4049.
80. Peng SL, Madaio MP, Hayday AC, Craft J. Propagation and regulation of systemic autoimmunity by gamma delta T cells. J Immunol 1996; 157: 5689-5698.
81. Peng SL, Craft J. T cells in murine lupus: propagation and regulation of disease. Mol Biol Rep 1996; 23: 247-251.
82. Peng SL Moslehi J, Robert ME, Craft J. Perform protects against autoimmunity in lupus-prone mice. J Immunol 1998; 160: 652-660.
83. Shlomchik MJ et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180: 1295-1306.
84. fyn in their activation and expansion. J Immunol 1997; 159: 2265-2273.
85. + cells of older lupus mice. Eur J Immunol 1997; 27: 1901-1910.
86. Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997; 99: 1936-1946.
87. Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101: 364-371.
88. Haas C, Ryffel B, LeHir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997; 158: 5485-5491.
89. lpr mice. J Immunol 1998; 161: 494-503.
90. Haas C, Ryffel B, LeHir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J Immunol 1998; 160: 3713-3718.
91. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 1052-1054.
92. Santiago M-L et al. Interleukin-l protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997; 185: 65-70.
93. Ibnou-Zekri N et al. Role of the major histocompatibility complex class II Ea gene in lupus susceptibility in mice. Proc Natl Acad Sci USA 1997; 94: 14654-14659.
94. d transgene-mediated protection from murine lupus. J Autoimmunol 1998; 11: 241-248.
95. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
96. Kotzin BL, Babcock SK, Herron LR. Deletion of potentially self-reactive T cell receptor specificities in L3T4, Lyt-2 cells of lpr mice. J Exp Med 1988; 168: 2221-2229.
97. + and abnormal lpr and gld cell populations. J Exp Med 1989; 170: 1869-1877.
98. Sidman CL, Marshall JD, VonBoehmer H. Transgenic T cell receptor interactions in the lymphoproliferative and autoimmune syndromes of lpr and gld mutant mice. Eur J Immunol 1992; 22: 499-504.
99. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1: 365-371.
100. Sytwu H-K, Liblau RS, McDevitt HO. The roles of Fas/APO-1 (CD95) ad TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996; 5: 17-30.
101. Russell JH, Rush B, Weaver C, Wang RD. Mature T-cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993; 90: 4409-4413.
102. Mogil RJ et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 1995; 7: 1451-1458.
103. + T cells. Nature 1995; 376: 181-184.
104. Rathmell JC et al. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-329.
105. Roark JH et al. Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus. J Exp Med 1995; 181: 1157-1167.
106. Kench JA, Russell DM, Nemazee D Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J Exp Med 1998; 188: 909-917.
107. Drake CG, Babcock SK, Palmer E, Kotzin BL. Genetic analysis of the NZB contribution to lupus-like autoimmune disease. Proc Natl Acad Sci USA 1994; 91: 4062-4066.
108. Morel L et al. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1: 219-229.
109. Kono DH et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 1994; 91: 10168-10172.
110. Drake CG et al. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. J Immunol 1995; 154: 2441-2445.
111. Vyse TJ et al. Backcross analysis of genes linked to autoantibody production in New Zealand white mice. J Immunol 1996; 157: 2719-2722.
112. Rozzo SJ, Vyse TJ, Drake CG, Kotzin BL. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proc Natl Acad Sci USA 1996; 93: 15164-15169.
113. Vyse TJ et al. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand Black mice. J Immunol 1997; 158: 5566-5570.
114. Mohan C, Morel L, Yang P, Wakeland EK. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997; 159: 454-460.
115. Mohan C et al. Genetic dissection of SLE pathogenesis. J Clin Invest 1998; 101: 1362-1372.
116. Watson ML et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992; 176: 1645-1656.
117. Wang Y et al. Host modifier genes affect mouse autoimmunity induced by the lpr gene. Am J Pathol 1997; 151: 1791-1794.
118. lpr mice. J Clin Invest 1998; 101: 696-702.
119. 1 mice. Int Immunol 1994; 6: 1857-1864.